NAP1L1抗体

+ +

•  

   

     Gel: 10%SDS-PAGE, Lysate: 40 μg, Lane 1-5: A549 cells, hela cells, mouse liver tissue, human liver tissue, hepG2 cells, Primary antibody: P08014(PGK1 Antibody) at dilution 1/850, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 20 seconds    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P08014(PGK1 Antibody) at dilution 1/40. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human brain  tissue using P08014(PGK1 Antibody) at dilution 1/40. (Original magnification: ×200)    

  
  

NAP1L1 (Nucleosome Assembly Protein 1 Like 1) is a conserved histone chaperone involved in chromatin remodeling, nucleosome assembly, and transcriptional regulation. It belongs to the NAP/SET family, sharing structural homology with proteins that bind histones H3-H4 to facilitate DNA replication and repair. NAP1L1 plays roles in cell cycle progression, embryonic development, and maintaining stem cell pluripotency. Dysregulation of NAP1L1 has been linked to cancers, neurodevelopmental disorders, and viral infections, making it a subject of interest in disease mechanisms.

Antibodies targeting NAP1L1 are essential tools for studying its expression, localization, and function. These antibodies are typically developed in hosts like rabbits or mice, using immunogenic peptides from conserved regions (e.g., C-terminal domains). They are widely employed in techniques such as Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF) to detect NAP1L1 in tissues or cultured cells. Validation often includes knockdown/overexpression controls to confirm specificity.

Research using NAP1L1 antibodies has revealed its overexpression in hepatocellular carcinoma, neuroblastoma, and glioblastoma, suggesting oncogenic potential. Conversely, reduced levels correlate with developmental defects. Such studies highlight NAP1L1’s dual roles in proliferation and differentiation, emphasizing its therapeutic and diagnostic relevance. Commercial NAP1L1 antibodies vary in clonality (monoclonal/polyclonal) and conjugation formats, enabling diverse experimental applications.